Erratum: Antenatal prediction of postpartum depression with blood DNA methylation biomarkers

Guintivano, Jerry; Arad, Marina; Gould, Tiffany; Payne, Jennifer L.; Kaminsky, Zachary

doi:10.1038/mp.2013.149

Cited by 9 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study found 44 risk variants, including a key regulator of the stress response 21 . PPD may be influenced by epigenetic factors in addition to genetic variables [22][23][24][25] .…”

Section: Pathophysiology Of Ppdmentioning

confidence: 99%

The FDA's Recent Approval of Zuranolone as the First Oral Treatment and its Implications for Postpartum Depression: ushering in a New Era of Hope; An Updated Review (Preprint)

Haris,

Mukhtar,

Mohiuddin

et al. 2024

Preprint

View full text Add to dashboard Cite

UNSTRUCTURED Introduction Childbirth often initiates a cascade of emotions, but for some women, it can lead to the onset of postpartum depression (PPD), characterized by a range of physiological and emotional changes. Despite its prevalence, PPD remains underdiagnosed, with significant implications for maternal health and well-being. The pathophysiology of PPD involves intricate interactions between hormonal, genetic, and environmental factors, influencing treatment approaches and outcomes. Methods This review examines the multifaceted nature of PPD, focusing on its epidemiology, pathophysiology, and therapeutic interventions. Relevant literature was identified through systematic searches of databases, including PubMed and Google Scholar, using keywords related to PPD, hormonal changes, genetic factors, and treatment modalities. Results Epidemiological studies reveal varying prevalence rates of PPD worldwide, with significant underdiagnosis posing challenges for effective management. Pathophysiological mechanisms involve complex interactions between hormonal fluctuations, genetic predispositions, and environmental stressors. Current therapeutic agents, including psychotherapy, antidepressants, and emerging treatments like brexanolone and zuranolone, offer varying degrees of efficacy and safety profiles. Discussion The recent FDA approval of zuranolone as an oral medication specifically designed for PPD represents a significant advancement in mental health care. While zuranolone shows promise for rapid symptom relief and increased treatment accessibility, concerns remain regarding its safety for breastfeeding women and potential side effects. Further research is needed to address these issues and optimize the use of zuranolone in clinical practice. Overall, zuranolone represents a crucial step forward in addressing the complex and debilitating symptoms of PPD, offering hope for improved outcomes and enhanced quality of life for affected individuals.

show abstract

“…One study found 44 risk variants, including a key regulator of the stress response 21 . PPD may be influenced by epigenetic factors in addition to genetic variables [22][23][24][25] .…”

Section: Pathophysiology Of Ppdmentioning

confidence: 99%

The FDA's Recent Approval of Zuranolone as the First Oral Treatment and its Implications for Postpartum Depression: ushering in a New Era of Hope; An Updated Review (Preprint)

Haris,

Mukhtar,

Mohiuddin

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

The search for peripheral biomarkers for major depression: Benefiting from successes in the biology of smoking

Philibert

Gunter

Kolassa

2014

American J of Med Genetics Pt B

View full text Add to dashboard Cite

The search for robust, clinically useful markers for major depression (MD) has been relatively unproductive. This is unfortunate because MD is one of the largest socio-economic challenges for much of the world and the development of reliable biomarkers for MD could aid in the prevention or treatment of this common syndrome. In this editorial, we compare the approaches taken in the search for biomarkers for MD to that of the more successful searches for biomarkers for tobacco use, and identify several substantive barriers. We suggest that many of the existing clinical repositories used in these biomarkers searches for MD may be of limited value. We conclude that in the future greater attention should be given to the clinical definitions, characterization of confounding environmental factors and age of subjects included in studies. © 2014 Wiley Periodicals, Inc.

show abstract

Blood-Based Biomarkers in Depression: Emerging Themes in Clinical Research

Uddin

2014

Mol Diagn Ther

View full text Add to dashboard Cite

There is growing interest in identifying blood-based biomarkers for depression. This brief review examines recent research in this area, using a focused literature search to identify emerging themes in current work pertaining to major depressive disorder (MDD). The results suggest that biomarker-based research in MDD is still in its relative infancy and is focused on answering two major questions: what biomarkers reliably distinguish individuals with MDD from those without MDD; and what biomarkers can identify or predict treatment responders versus non-responders? However, a number of issues limit the potential utility of positive findings in each case; chief among these is the lack of truly independent replication cohorts in which to validate initial findings. Some promising results have emerged pertaining to predictors of antidepressant effectiveness and, if validated by future independent studies, these may hold promise as targets to be developed within clinical settings and may ultimately guide treatment regimens for patients suffering from MDD.

show abstract

Erratum: Antenatal prediction of postpartum depression with blood DNA methylation biomarkers

Cited by 9 publications

References 0 publications

The FDA's Recent Approval of Zuranolone as the First Oral Treatment and its Implications for Postpartum Depression: ushering in a New Era of Hope; An Updated Review (Preprint)

The FDA's Recent Approval of Zuranolone as the First Oral Treatment and its Implications for Postpartum Depression: ushering in a New Era of Hope; An Updated Review (Preprint)

The search for peripheral biomarkers for major depression: Benefiting from successes in the biology of smoking

Blood-Based Biomarkers in Depression: Emerging Themes in Clinical Research

Contact Info

Product

Resources

About